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A B S T R A C T
Multiple myeloma (MM) is the most frequent cancer to involve the skeleton with patients developing osteolytic
bone lesions due to hyperactivation of osteoclasts and suppression of BMSCs differentiation into functional
osteoblasts. Although new therapies for MM have greatly improved survival, MM remains incurable for most
patients. Despite the major advances in current anti-MM and anti-resorptive treatments that can significantly
improve osteolytic bone lysis, many bone lesions can persist even after therapeutic remission of active disease.
Bone marrow mesenchymal stem cells (BMSCs) from MM patients are phenotypically distinct from their healthy
counterparts and the mechanisms associated with the long-term osteogenic suppression are largely unknown. In
this review we will highlight recent results of transcriptomic profiling studies that provide new insights into the
establishment and maintenance of the persistent pathological alterations in MM-BMSCs that occur in MM. We
will we discuss the role of genomic instabilities and senescence in propagating the chronically suppressed state
and pro-inflammatory phenotype associated with MM-BMSCs. Lastly we describe the role of epigenetic-based
mechanisms in regulating osteogenic gene expression to establish and maintain the pro-longed suppression of
MM-BMSC differentiation into functional OBs.
1. Introduction
Multiple Myeloma (MM) is a heterogeneous malignancy character-
ized by abnormal clonal plasma cell infiltration in the bone marrow [1].
Unlike solid tumors, which typically metastasize to distinct sites from
the primary tumor, MM is usually widespread in multiple sites within
the bone marrow. The bone marrow provides a specialized and highly
supportive microenvironment in which interactions between MM and
host cells, as well as components of the extracellular matrix (ECM)
drive tumor development, progression and drug resistance [2]. Bone
marrow mesenchymal stem cells (BMSCs) provide a special class of
multi-potent cells, which can give rise to a variety of cell types, in-
cluding osteoblasts (OB), osteocytes, adipocytes, chondrocytes, muscle
cells and reticular fibroblasts [3]. These specialized cell types con-
tribute to the well-organized architecture of the bone marrow, support
the survival and differentiation of diverse lineages of hematopoietic
cells and regulate bone formation and resorption. In addition to
maintenance of bone homeostasis, immunomodulatory features of
BMSCs control multiple aspects of MM pathophysiology and its asso-
ciated bone disease [4]. Infiltrating MM cells co-opt a variety of
mechanisms to suppress BMSC differentiation into functional OBs,
which in turn enhances their support of MM cell growth, survival, and
drug resistance [5, 6]. Even with the advancement of proteasome in-
hibitors and therapy regimens that combine chemotherapy, autologous
stem cell transplantation, and maintenance strategies, which were
shown to significantly improve bone formation [7] and enhance re-
mineralization of pelvic lesions in MM patients [8], many bone lesions
persist even after MM eradication due to uncoupled bone remodeling
[9]. This further increases morbidity, mortality and medical costs. Re-
search studies of MM bone disease (MMBD) have revealed a multiplicity
of deregulated signaling molecules and receptor pathways associated
with anti-osteogenic, pro-osteolytic and growth-supporting properties
of the MM bone microenvironment (BME). However, the mechanisms
associated with prolonged suppression of OB differentiation of MM-
MSCs (MM-BMSCs) that occur even in the absence of signals from MM
cells are still unclear. In this review, we highlight some of the pheno-
typic characteristics associated with the senescence and tumor-pro-
moting features of MM-BMSCs. We discuss genome-wide transcriptional
changes, chromosomal alterations as well as chromatin-based epige-
netic mechanisms that contribute to osteogenic suppression of BMSC
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progenitors in MM bone disease.
1.1. Phenotypic alterations in BMSCs in mM
BMSCs are multipotent progenitor cells with self-renewal capacity
and tri-lineage potential to differentiate into various cell types of the
mesoderm lineage, including OBs, adipocytes and chondrocytes
[10,11]. The multi-lineage differentiation potential of BMSCs is highly
dependent on their developmental state and interactions with their
microenvironment in healthy and disease states [12]. For example,
during aging and in various inflammatory and malignant conditions,
the normal epigenetic reprograming and differentiation capacities of
BMSCs into functional OBs are compromised, resulting in suppression
of osteogenesis and increased adipogenesis. Since MM is predominantly
a disease of the elderly with a median age at diagnosis of approximately
70 years [13], it is important to note the striking similarities between
the changes that occur in BMSCs of older patients and those detected in
BMSCs in pathologic inflammatory conditions that affect the marrow. It
is important to consider whether age-related changes in BMSCs con-
tribute to development of MM and/or progression from its precursory
state, monoclonal gammopathy of undetermined significance (MGUS)
to MM, or if the observed senescence-like and anti-osteogenic pheno-
type of MM-BMSC only results from their exposure to MM cells. Dis-
tinguishing between the relative contributions of aging per se and MM
cell exposure on BMSCs has been very difficult to dissect, in part be-
cause most of the current in vivoMMmodels have significant limitations
[14]. However, a recent metagenomic analysis of the C57BL/KaLwRij
(KaLwRij) murine MM model [15], which shares many phenotypic si-
milarities and clinical features associated with human MGUS progres-
sion to MM, demonstrated that genetic alterations in both pre-malig-
nant B-cells and the cells of the host microenvironment, such as BMSCs
and macrophages, contribute to the development of MM. This study
suggests that development of malignant plasma cells together with
potentially age-related alterations of multiple cell types within the BM
may contribute equally to creating a permissive environment in the
initial stages and progression of MM [15].
Although multiple studies have reported significant differences be-
tween normal and MM-BMSCs, there is no consensus among in-
vestigators on what these changes are. Several reports indicated that
BMSCs derived from normal donors, MGUS and MM patients have si-
milar proliferation capacities [16,17] and that the proliferation rate of
the MM-BMSCs did not correlate with the number of osteolytic lesions
in MM patients [18]. These investigators found that MM-BMSCs pro-
duced abnormally high levels of cytokines that altered hematopoietic
cell support and impaired osteogenesis. In contrast, Garderet et al. [19]
reported that patient derived MM-BMSCs displayed impaired pro-
liferation due to decreased levels of growth factor receptors and ele-
vated DKK1 and IL6 expression as compared to HD-BMSCs. Further-
more, MM-BMSC expansion rate was worse in patients with advanced
disease and lytic lesions [19]. Discrepancies in MM-BMSCs research
studies such as these may arise from differences associated with the
methodologies used in the characterization, isolation, expansion, and
study design of MM-BMSCs as well as intrinsic patient-specific varia-
bility. In many cases, in vitro expansion of BMSCs is often necessary, due
to the very low frequency (0.001–0.01%) of BMSCs, especially in bone
marrows of elderly MM patients [20]. Typically, bulk bone marrow cell
populations are subjected to plastic adherence and ex vivo expansion in
proliferating media for several weeks. Increasing evidence suggests that
long-term cultures of isolated BMSCs changes their phenotypic prop-
erties due to DNA methylation and epigenetic transformations [21].
However, what has been clearly shown is that the phenotypic altera-
tions in BMSCs in MM that contribute to the drug resistance and tumor
growth of MM cells result from exposure of BMSCs to MM cells in pa-
tients and/or MSC-lineage cell lines exposed to MM cells. These phe-
notypic features of MM-BMSCs include that they have suppressed os-
teogenic potential, express inflammatory cytokines, increased
adipogenic differentiation and support MM growth.
Multiple mechanisms appear to contribute to changing the pheno-
type of normal BMSCs to tumor-promoting BMSCs in MM. For example,
BMSCs isolated from MM patients can secrete protective soluble factors
that confer resistance to Apo2 ligand/TRAIL-mediated apoptosis of MM
cells [22]. Grigorieva et al. [23] reported that MM patient-derived
BMSCs provided sufficient amounts of interleukin 6 (IL6) to effectively
protect immature CD38+CD45+ MM cells from the cytotoxic effects of
dexamethasone. In another report, the IL6-independent U266, ARH-77,
HS-SUI-tan, and IM-9 cell lines exhibited decreased DNA synthesis
when co-cultured with healthy donor BMSCs, which did not occur when
they were co-cultured with MM-BMSCs [24]. MM patient-derived
BMSCs also protected the IL6–dependent MM cell line, INA-6, and
primary CD138+ MM cells from the cytotoxic effects of the IL6 receptor
antagonist Sant7 and/or apoptosis induced by anti-gp130 monoclonal
antibody treatment in vitro [25]. Hao at al. [26] showed that the U266
and H929 MM cell lines co-cultured with MM-BMSCs were protected to
a greater extent from bortezomib-induced growth inhibition and
apoptosis than MM cells co-cultured with normal donor (HD) BMSCs.
They found that MM-BMSCs expressed higher levels of the adhesion
molecules, ICAM-1 and VCAM-1, and secreted higher levels of the
tumor-promoting factors, IL6 and VEGF, compared to HD-BMSCs [26].
Similar results were reported by Gupta et al. [27]. Consistent with these
observations, Nefedova et al. [28] showed that media conditioned by
HD-BMSCs did not protect MM cells from mitoxantrone-induced
apoptosis, but after co-culture with MM cells, the BMSCs secreted so-
luble tumor-promoting anti-apoptotic factors. Further, co-culture of
MM cells with BMSCs in direct contact provided significantly more
protection from mitoxantrone treatment than separating the cells in
transwell co-cultures [28]. In addition, exosomes have been implicated
in exchanging proteins, DNA, mRNA, as well as non-coding RNAs be-
tween adjacent tumor cells and BMSCs in the local microenvironment
[29]. Exosomes derived from MM patient bone marrow serum can
prime HD-BMSCs to support the survival and growth of MM plasma
cells [30]. Roccaro et al. [31] found that the amounts of the MM-in-
hibitory microRNA (miRNA) miR-15a were decreased in MM-BMSCS
exosomes, and that the levels of oncogenic proteins, cytokines, protein
kinases and adhesion molecules in exosomes differed between MM and
normal BMSCs. Additionally, while exosomes from normal BMSCs in-
hibited MM cell proliferation, MM-BMSCs-derived exosomes promoted
dissemination of MM cells in the bone marrow and enhanced tumor
growth in vivo [32]. However, none of these mechanisms can explain
the persistent suppression of OB differentiation that can occur in MM
patients.
Therefore, in the following sections we highlight recent findings and
provide insights into phenotypic alteration of myeloma exposed BMSCs.
We will focus on genomic and epigenetic-based mechanisms in the
context of establishment and maintenance of osteogenic suppression.
We will discuss the role that epigenetic control of MSC-lineage
switching from osteogenic to adipogenic commitment plays in MMBD.
Lastly, we will address the role of chromatin remodeling enzymes in
MMBD and the potential of employing small molecule epigenetic in-
hibitors currently used in the MM research as therapeutics and bone
anabolic agents in the prevention or repair of osteolytic lesions in MM.
1.2. Transcriptomic characterization of the MM-BMSCs
Development of microarrays and next-generation sequencing (NGS)
technologies has provided new approaches for assessing the genomic
and epigenetic changes associated with the origins, progression and
evolution of malignant diseases [33]. A search of the Gene Expression
Omnibus (GEO) repository and available published NGS data sets de-
monstrate that MM plasma cells have been the primary focus of com-
prehensive genomic, transcriptomic and epigenetic studies in MM.
Much has been learned about the changes in transcriptome signatures
driven by genetic abnormalities and oncogenic transformations that
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occur in MM cells [34]. New appreciation for a global picture of 3-
dimensional (3D) topological architecture and chromatin landscapes in
the context of deregulated MM transcriptome signatures opens a new
frontier of myeloma biology interrogation and drug targeting [35].
Gene expression profiling (GEP) is becoming a new tool in precision
medicine for assessing myeloma subtypes and survival outcomes with a
focus on drug treatment responses in high-risk MM patients [36]. The
study by Botta at al. [37], found that inflammatory and cytokine/che-
mokine-mediated pathways are among the highest deregulated gene
sets in myeloma evolution. Out of 20 selected candidate genes, differ-
ential expression of 8 genes encoding immunomodulators IL8, IL10,
IL17A, CCL3, VEGEFA, EBI3, and NOS2 most accurately predicted
clinical outcome and correlated with MM disease stage progression
[37]. In addition to prognostic features, transcriptomic analyses have
provided important insights into deregulated oncogenic and pro-
liferative pathways in MM cells exposed to combination treatment with
EZH2 and pan-HDAC inhibitors [38], as well as tofacitinib-mediated
reversal of microenvironmental support for MM survival [39]. Recent
comprehensive analysis of 255MM patient samples demonstrated the
importance of aberrant expression of fusion transcripts in MM pro-
gression [40]. Interestingly, alternative intronic polyadenylation
known to generate various isoforms of protein coding genes has been
recently defined in MM cells. In this report, global loss of intronic
polyadenylation isoforms contributed to lenalidomide resistance and
correlated with decreased progression-free survival of MM patients
[41]. Furthermore whole transcriptome sequencing study by Samur and
colleagues [42] reported that 869 long intergenic non-coding (lincRNA)
were differentially expressed in MM as compared to normal plasma
cells. More importantly, expression of 14 lincRNAs correlated with low-
and high-risk disease stratification, which suggests their potential use in
disease detection as well as prognostic factors in clinical outcome of
myeloma disease [42]. Advancements in NGS sequencing at the single
cell level enabled myeloma researchers to dissect and characterize cell
sub-populations from bulk MM tumors. Comparative single cell
genomic and global whole-exome sequencing analyses has led to
identification of phylogenic divergence of myeloma cell subclones
giving raise to the heterogeneity of myeloma tumors [43]. Using NOD/
SCID-IL2RγNULL mouse xenografts Melchor et al. [43] further confirmed
that selective pressures and the occurrence of new mutations contribute
to clonal diversity during MM tumorigenesis. Newly emergent clones
exhibit more resistant phenotypes and better survival properties during
drug treatment or mouse engraftment [43]. Consistent with this, study
by Mitra et al. [44] employed targeted transcriptome analyses of drug
pre-exposed cell lines and naïve primary MM cells, to determine the
proteasome inhibitor drug response GEP signature of distinct MM sub-
populations. Collectively NGS technology greatly enhanced our un-
derstanding of deregulated gene expression profiles associated with MM
heterogeneity and treatment resistance. The use of transcriptomic sig-
natures for classification and diagnostic purposes in determining clin-
ical outcome and tailored patient specific therapy are an exciting
frontier of myeloma research. However, herein we present an addi-
tional layer of complexity in predicting disease evolution by accounting
for the important changes and contributions of the bone marrow mi-
croenvironment to molecular pathogenesis of MM progression and drug
resistance. The major clinical importance is to characterize the mole-
cular changes that occur in the bone marrow in order to reverse its
tumor fostering properties and enhance bone formation. Recent studies
employing whole-transcriptome analyses of BMSC interactions with
MM cells have verified previously known genes that are involved in
these interactions and identified several new deregulated pathways and
gene targets that play a role in MM cell homing to bone (Fig. 1).
One of the original MM-MSCs transcriptomic studies by Corre et al.
[17] identified 127 annotated genes that were differentially expressed
between normal and MM patient BMSCs. Almost 50% of these de-
regulated transcripts were associated with MM cell-BME crosstalk.
These transcripts included genes encoding factors involved in cell
communication, receptor signaling and extracellular matrix activity.
These authors identified several upregulated genes, known to play a
role in the pathogenesis of MM, including MM-growth promoting mo-
lecules such as Amphiregulin (AREG) [45,46], the pro-inflammatory
cytokines IL1b and IL6 [47] as well as DKK1, a suppressor of OB dif-
ferentiation. Among the newly identified genes they reported were pro-
osteolytic protein growth differentiation factor 15 (GDF15) [48], pro-
angiogenic and chemotactic factor secretogranin II (SCG2), [17] and
plasminogen activator inhibitor 1 (PAI-1), which were associated with
disease progression of MM patients [49]. Giuliani and co-workers
analyzed the transcriptional profiles of primary patient-derived BMSCs
and OBs from normals (N), MGUS and MM patients [18]. This study
then correlated the observed gene expression differences with the oc-
currence of lytic lesions among the MM patient samples. The molecular
signatures of the three sample sets (N, MGUS and MM) identified genes
predominantly involved in cell adhesion, cell cycle, transcriptional
regulation and cell proliferation [18]. While there was not a clear dis-
tinction between MGUS and MM samples, 78 genes were differentially
expressed between N and MM patient samples (in both isolated BMSCs
and OBs) including HOXB2, 6 and 7, which are known to regulate
mesenchymal cell lineage self-renewal and adipogenic commitment
[50]. Genes predominately related to nucleic acid metabolism, RNA
processing and transcription regulation were upregulated in MM-
BMSCs from patients with lytic lesions, while extra cellular matrix
(ECM) structural constituents, the WWOX/FOR tumor suppressor gene
and WNT6, an osteogenic factor, were downregulated, consistent with
their enhanced adipocytic phenotype [51]. The WWOX/FOR gene is
frequently mutated in several solid tumors [52] andWWOX/FOR loss of
function has been implicated in osteosarcomas [53]. However, its role
in MMBD has not yet been defined. DCN, a gene encoding a small
leucine-rich proteoglycan decorin, was downregulated to a greater ex-
tent in MM-BMSC/OBs from osteolytic than nonosteolytic MM patient
samples [18]. Ida et al. also showed that decorin levels were down-
regulated in bone marrow plasma from both MGUS and MM patients as
compared to healthy donors [54]. Decorin is primarily released by
BMSCs and OBs [55] and exerts direct anti-MM effects by inducing
apoptosis via activation of p21WAF1 [56] and blocking hepatocyte
growth factor-induced migration and viability of MM cells [54]. In-
direct effects of decorin on MM survival were also reported by Li et al.
[56], who found that decorin decreased the capacity of osteoclasts to
support primary MM cell survival.
More recently, Garcia-Gomez et al. [57] compared the transcrip-
tional profiles of HD-BMSCs or MM patient BMSCs co-cultured for 24
hours in a direct-transwell culture system with the MM1.S human MM
cell line. They found that normal and MM-derived BMSCs expressed a
common upregulated functional gene signature after co-culture with
MM1.S cells that included bone-ME regulatory genes involved in che-
mokine/cytokine and inflammatory responses, angiogenesis, prolifera-
tion, apoptosis, skeletal development, integrin-mediated adhesion and
ECM remodeling. One of the highest expressed genes in MM and HD-
BMSCs following MM-co-culture was IL8, which promotes angiogenesis,
proliferation and chemotaxis of MM cells and stimulates osteoclasto-
genesis, that have important roles in the pathogenesis of MMBD (26). In
support of these results, elevated IL8 levels were detected in serum of
MM patients. CXCL1, CXCL5 and CXCL6, which are C-X-C chemokine/
cytokine that enhance MM growth and angiogenesis, were also upre-
gulated. Interestingly, these authors suggested that interactions of MM
cells with BMSCs reduced the growth and induced early senescence of
BMSCs. BMSC senescence is now emerging as an important underlying
contributor to the prolonged suppression of OB differentiation in MM-
BMSCs [29, 58–60]. Several gene sets were found to be specifically
upregulated in MM-BMSCs. The upregulated genes were involved in
RNA processing and splicing, activation of the ubiquitin-proteasome
pathway, cell cycle regulation, cellular stress response, and the non-
canonical Wnt signaling pathway. Neuregulin-3 (NRG3) and Norrie
disease protein (NDP) were identified as putative candidates
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contributing to the progression of MMBD. NRG3 promoted MM cell
proliferation and NDP increased RANKL-independent osteoclast for-
mation [57]. Most likely, the gene changes induced by MM cells in HD-
BMSCs may reflect genes involved in early changes in BMSCs during
MM initiation, while genes uniquely deregulated in MM-patient BMSCs
more likely participate in the prolonged OB suppression and enhanced
adipogenic features of the later stages of lytic bone disease.
Global analysis of direct MM contact-induced gene expression
changes in the BMSCs by Dotterweich at al. [61] provides new insights
into deregulated osteogenic and angiogenic pathways at the bone-
tumor interface. In this study, the BMSC-dependent plasmacytoma cell
line, INA-6, was cultured in a direct contact with primary older donor
BMSCs (average age 63) or BMSCs pre-differentiated in osteogenic
media for 14-days (OP-MSC). They found that after contact with INA-6
cells, 991 and 552 probe sets were differentially expressed in BMSC and
OP-MSC respectively. Pre-differentiated OP-MSCs had fewer gene ex-
pression changes after MM contact, consistent with previous reports
[18] and studies suggesting that mature OBs may exhibit anti-MM
properties [54–56,62]. Gene expression profiles common to both
BMSCs and OP-MSCs exposed to MM, were enriched in tumor-pro-
moting genes involved in disease activity, tumor cell homing, angio-
genesis, osteoclastogenesis, epithelial differentiation, cell-cell adhesion,
and lipid and cholesterol storage. Consistent with the abnormal bone
remodeling in MM, several genes known to interfere with bone meta-
bolism including genes coding for anti-osteogenic factors APLN, STC1
and receptors/ligands OSMR, MCHR1, SEMA4D, EFNB2 were ex-
clusively upregulated in undifferentiated BMSC. Of specific interest,
adipose tissue-derived factor Angiopoietin-like 4 (ANGPTL4) was
among the highest upregulated genes induced by MM [61]. Originally
discovered as an endocrine regulator of lipid metabolism, ANGPTL4
affects osteoclast-mediated bone resorption, cartilage degradation and
angiogenesis and has been implicated in regulating the critical balance
between bone marrow adiposity and fracture risk in osteolytic disorders
[63]. Importantly, the authors showed that ANGPTL4 was specifically
elevated in BMSCs by INA-6 cell contact and not by contact with
healthy donor CD19+ B cells [61]. These studies suggest that under-
standing the changes in gene networks in BMSCs induced by cross-talk
with MM cells should provide a mechanistic basis for development of
new therapeutic approaches for MMBD.
The transcriptomic studies described above have yielded significant
insights into deregulated gene expression profiles and signaling path-
ways associated with phenotypic changes of BMSCs that create a per-
missive microenvironment for homing and growth of MM cells in the
bone marrow. However, although the observed gene expression
changes in skeletal precursors are striking, they occur within hours of
physical contact with MM cells. It would also be very beneficial to
compare these gene profiles with those obtained after extended MM co-
culture, and after co-culture with distinct genotypic subtypes of primary
CD138+ MM cells isolated from patients with low and high-risk MM
and different levels of bone disease. Further, these studies did not de-
termine which of the deregulated gene expression profiles they found
persists after MM-cell removal. This could provide key insights into the
mechanisms responsible for the prolonged osteogenic suppression,
which continues in the absence of ongoing signals from MM cells.
1.3. Genomic alterations and senescence of MM-BMSCs
Genomic aberrations in patient-derived MM-BMSCs have been
identified in several studies [59,64,65]. An array-based comparative
genomic hybridization (array-CGH) analysis detected the presence of
several non-recurrent chromosomal gains and losses (41Mb size) to-
gether with a discrete pattern of “hot spot” of genomic alterations in
Fig. 1. Gene expression signatures in MM-BMSCs.
Depicted are transcriptional signatures of patient
derived BMSCs and BMSCs co-cultured in a direct
contact with MM cells, which were identified in
studies using gene expression microarrays
[17,18,57,60,61]. Shared gene categories reported
in the studies are shown in the middle of the dia-
gram and represent upregulated (red arrow) and
downregulated (blue arrow) gene signatures, which
are common to MM-BMSCs. Each side of the dia-
gram represents unique functional categories iden-
tified in the gene expression sets for both MM-
BMSCs and MM co-cultured BMSCs. (For inter-
pretation of the references to color in this figure
legend, the reader is referred to the web version of
this article.)
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BMSCs derived from MM patients [64]. In most studies of genetically
altered MM-BMSCs, the authors found deregulated expression of genes
implicated in MM-BMSCs interactions, OB differentiation and MM-cell
survival. Some of the significantly deregulated genes included bone
morphogenetic protein 10 (BMP10), ephrin type-B receptor 1 (EPHB1),
fibulin 5 EGF-like protein (FBLN5), receptors expressed in lymphoid
tissues e.g. (RELL1) and ADAM metallopeptidase with thrombospondin
type 1 motif 17 (ADAMTS17). However, this study did not correlate
these distinct gene expression profiles with specific phenotypic changes
in MM-BMSCs. While the authors do point out the possibility that in
vitro culture conditions may have favored selection of genomically
unstable MM-BMSC clones, these genomic imbalances were absent in
identically expanded HD-BMSCs. These results suggest that the genomic
instability was associated with MM exposure, rather than being an in
vitro expansion artifact, and may contribute to the prolonged osteo-
genic-defect in MM-BMSCs [64].
MM-induced early senescence of BMSCs also appears to contribute
to the abnormalities present in MM-BMSCs (Fig 2). Senescence is a form
of the cellular stress response often associated with degenerative and
hyperplastic pathologies of aging. Due to dysfunctional telomeres,
genotoxic stresses cause accumulation of DNA damage, perturbations to
chromatin organization and strong mitogenic signals, so that senescent
cells stop proliferating and undergo cell cycle arrest [66]. A causal role
for senescent BMSCs in bone loss with aging has been well documented,
and clinical targeting of these cells elicits both anti-resorptive and bone
anabolic effects [67]. Li et al. reported that increased telomere length in
BMSCs isolated from MM patients correlated with elevated expression
of pro-inflammatory cytokines IL6 and MIP1α as compared to healthy
donors [65]. However, consistent with other reports of possible early
senescence of MM-BMSCs, these BMSCs exhibited decreased pro-
liferative capacity but the osteogenic potential of these cells needs to be
further evaluated [65]. While these results are intriguing, further me-
chanistic studies together with using BMSCs that are expanded less in
vitro are needed to better link the changes in telomere length with
functional abnormalities in MM-BMSCs. Berenstein et al. [59], showed
that copy number variation and hypomethylation of the DLK1-DIO3
and C19MC genomic clusters were implicated in the senescence-asso-
ciated abnormalities in MM-BMSCs isolated from patients. These
genomic alterations correlated with overexpression of miR-485-5p and
miR-519d, which increased senescence associated β-galactosidase ac-
tivity (SA-βGalA) and S-phase cell cycle arrest. This report is consistent
with previous observations that implicated involvement of miRNAs in
MM pathology with potential roles in inflammation-induced cellular
senescence [68,69]. Interestingly, the senescent phenotype of MM-
BMSCs was reversed after direct and transwell co-cultures with the
human myeloma KMS12-PE cells [59]. Interactions with KMS12-PE
MM-cells caused downregulation of the senescence-stimulating miR-
485-5p and increased the proliferative capacity of the BMSCs. A recent
microarray study revealed that the gene expression profile of patient-
derived MM-BMSCs closely resembles that of replicative senescent
human BMSCs [60]. Comparison of age matched healthy donor BMSCs
with MM-BMSCs from patients that had not received anti-MM therapy
revealed 646 differentially expressed probe sets between them. The
downregulated genes (348) were primary associated with important
biological functions pertaining to cell cycle, DNA repair, M phase
chromosome, DNA metabolism and microtubule cytoskeleton regula-
tion. The decreased expression of cell cycle activators (cyclins A, B, E,
D, H; cyclin dependent kinases (CDKs) 1, 2, 4, 6; or CDC25A, B and C)
was consistent with the increased expression of senescence-associated
β-galactosidase, enlarged cell size and reduced proliferative capacity of
MM-BMSC, due to increased accumulation of cells at S-phase. The MM-
BMSCs also had decreased expression of osteogenic activators and up-
regulation of OB antagonists together with an impaired mineralization
potential. It is important to note that senescent abnormalities were less
apparent in BMSCs from patients that had previously received anti-MM
therapy [60].
While senescent cells exhibit loss of proliferative capacity and os-
teogenic potential [70], they remain viable and metabolically active,
with abnormal secretion of pro-inflammatory senescence-associated
secretory profile (SASP) molecules [71]. Ozcan et al. applied oxidative
stress, DNA damage and replicative exhaustion to trigger senescence in
BMSCs to evaluate the effects of acute and chronic senescent BMSC
SASP on MM cell survival [29]. Conditioned media derived from both
acute and chronically induced senescent BMSC exhibited anti-MM ef-
fects and stimulated apoptosis and/or senescence of ARH-77MM cells.
Mass spectrometry analysis demonstrated that the content of the se-
nescent BMSC secretome was profoundly changed when senescent
BMSCs were subjected to co-culture with MM cells for 24 h. The BMSC
secretome of BMSC co-cultured with MM cells lacked pro-senescent
molecules and was enriched for anti-apoptotic, cancer growth pro-
moting and pro-metastatic factors. Further, conditioned media from
MM primed senescent BMSCs supported the growth of ARH-77 cells
[29]. This suggests that while similar phenotypic mechanisms may be at
play, MM-BMSCs are not equivalent to senescent HD-BMSCs. Lyso-
phosphatidic acid (LPA) receptors 1 and 3 signaling has recently been
implicated in modulating the senescent state and MM tumor promoting
properties of MM-BMSCs [58]. LPA1 and LPA3 transduce opposite
signals to tumor-surrounding BMSCs and determine if these cells enter a
pro-senescent or anti-senescent state, respectively. Kanehira et al. found
that LPA1mRNA was increased in MM patient BMSCs, which correlated
Fig. 2. Mechanisms underlying senescent phenotype of MM-BMSCs. Genomic
alteration, miRNA and altered receptor LPA1 receptor signaling are contributing
features to the senescent and tumor promoting phenotype of MM-BMSCs. Co-
cultures of BMSCs with MM cells were shown to decrease expression of Dicer1
and subsequent processing of miR-93/miR-20a. This resulted in elevated ex-
pression of the cell cycle inhibitor p21WAF1 and initiated senescence and tumor-
supporting phenotype of the MM-BMSCs [73]. Copy number variation and hy-
pomethylation of the DLK1-DIO3 and C19MC genomic clusters caused over-
expression of miR-485-5p and miR-519d, which increased senescence associated
β-galactosidase activity (SA-βGalA) and S-phase cell cycle arrest [59]. The mi-
croarray study by Andre et al. [60], identified 348 downregulated genes with
important biological functions in MM-BMCSs as compared to HD-BMSCs. To-
gether with downregulated osteogenic factors, the identified gene signatures
were associated with replicative senescence of MM-BMCSs. Increased telomere
length has been correlated with elevated expression of pro-inflammatory cyto-
kines IL6 and MIP1α and reduced cell proliferation of MM-BMSCs [65]. Lyso-
phosphatidic acid receptor 1 (LPA1) was shown to modulate the senescent state
and pro-inflammatory properties of MM-BMSCs. LPA1 signaling induced cell
cycle arrest, promoted cellular senescence and enhanced the angiogenic and
tumor-supporting properties of MM-BMSCs [58].
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with their senescent phenotype. They showed that LPA1 silencing sti-
mulated cell cycle progression, inhibited cellular senescence and trans-
differentiation of BMSCs into tumor-associated fibroblasts (TAFs).
Further, when IM-9MM cells were co-transplanted with BMSCs in
which LPA1 was inhibited using siRNA or the small molecule inhibitor
Ki16425, tumor growth and vascularization in a mouse MM xenograft
model was significantly reduced. In contrast, BM-MCSs with LPA3
knockdown and treated with IM-9MM conditioned media readily
transdifferentiated into senescent-like TAFs, and promoted tumor
growth in vivo [58].
Dicer1 has also been shown to be involved in MM-induced BMSC
senescence. Dicer1 is part of a multiprotein RNA-induced silencing
complex (RISC), which facilitates microRNA-guided post-transcrip-
tional mRNA regulation [72]. Knockdown of Dicer1 expression in
BMSCs from healthy controls induced growth arrest, promoted cellular
senescence and increased the tumor-supporting capacity of BMSCs. Si-
milarly, co-culture of BMSC with MM cells decreased expression of
Dicer1, reduced expression of miR-93/miR-20a and elevated expression
of the cell cycle inhibitor p21WAF1 in BMSCs. This resulted in senes-
cence and increased the tumor-supporting capacity of the MM-BMSCs
[73]. Collectively, these studies suggest that enhanced senescence is a
contributing factor to the functional changes induced in MM-BMSC by
MM cells. It is still unclear if senescence of MM patient BMSCs con-
tributes to OB suppression in the MM microenvironment in vivo, or if
senescence of MM-BMSC is a result of removal of BMSCs from their BM
niche with in vitro culturing that occurs in the absence of MM stimuli ex
vivo. The unexpected findings reported by Berenstein et al. [59] that
exposure of MM-BMSCs to MM cells reversed senescence of MM-BMSCs,
suggests that a better understanding of the cause of MM-BMSC senes-
cence is needed before therapy aimed at reversing senescence to relieve
the impaired osteogenesis of MM-BMSCs is undertaken.
1.4. Chromatin regulation in MM-exposed BMSCs
Chromatin remodeling enzymes play an integral part in epigenome
regulation by detecting (readers), adding (writers) and removing (era-
sers) active and repressive histone marks that allow for local chromatin
alterations that control gene expression [74]. Key examples of epi-
genome flexibility are “bivalent” chromatin domains, which contain a
combination of activating histone H3 lysine 4 tri-methylation
(H3K4me3) and repressive H3K27me3 chromatin marks that maintain
them in a quiescent state. Bivalent domains were initially identified as a
key property of pluripotent embryonic stem cells and are associated
with chromatin-modifying complexes and pre-loaded transcription
machinery at promoters or enhancers that maintain gene expression at
repressed or low levels. This “poised state,” allows for rapid gene ac-
tivation by appropriate stimuli such as differentiation factors [75,76].
Increasing evidence demonstrates that disturbances in the methylated
states of bivalent chromatin and deregulation of the corresponding
genes encoding developmental regulators and transcription factors are
a prominent feature in cancer [77].
We recently showed that epigenetic-based mechanisms contribute
to the initiation and persistence of osteogenic suppression of MM-
BMSCs (Fig. 3)[78–80]. We found that upregulation and enhanced
binding of GFI1, a transcriptional repressor, to a novel GFI1-response
element within the RUNX2 promoter mediated the sustained suppres-
sion of osteogenesis [78,80]. The role of RUNX2/CBFA1 during OB
differentiation is well-established [81], and inhibition of its transcrip-
tion is associated with impaired differentiation of MM-exposed human
pre-osteoblasts (preOBs) and decreased bone formation of osteogenic
progenitor cells from BM biopsies of MM patients with osteolytic lesions
[82]. BMSCs after coculture with MM cells, BMSC from MM-bearing
mice or MM-BMSCs isolated from MM patients had elevated levels of
GFI1 compared to normal controls [57,80,83]. Both direct cell contact
or exposure of BMSCs to TNFα and IL7, which are released by MM cells,
increased GFI1 levels and repressed RUNX2mRNA and protein levels in
MC4 pre-OBs or naïve primary BMSCs [80]. BMSCs isolated from GFI1-
knockout mice were significantly resistant to MM-induced OB sup-
pression. Further, siRNA knockdown of GFI1 in MM-exposed MC4 pre-
OBs and BMSCs from MM patients significantly restored expression of
RUNX2 and OB differentiation markers. In support of GFI1’s repressive
role in the BMSC cell lineage, Wang et al. [84] showed that down-
regulation of GFI1 in response to AMPK activation in MC4 pre-OBs
upregulated Osteopontin (OPN) gene expression, which promoted os-
teogenesis. In addition to RUNX2, OPN is the second known direct
target of GFI1 in pre-OBs.While additional GFI1 targets in MM-BMSCs/
pre-OBs remain to be determined, it is interesting to note that GFI1 was
among the highest represented transcription factors in a bioinformatic
analysis of putative transcription factor binding sites in the promoters
of deregulated genes in BMSCs cocultured with MM cells [57]. Further,
GFI1 expression was also elevated in patient-derived BMSCs after MM
co-culture in that study [57]. GFI1 can interact with several chromatin
modifiers to repress gene expression [85,86] In MM-exposed BMSC
cells, GFI1 acts as a platform for formation of a repressive complex
containing EZH2, histone deacetylase 1 (HDAC1) and lysine-specific
demethylase 1 (LSD1) [78] that silences expression of RUNX2 (Fig. 3).
Recruitment of the histone-modifying complex correlated with the
presence of repressive chromatin architecture at RUNX2, with de-
creased H3K4me3, H3K36me3 and acetylated H3K9ac marks. The
transcriptionally permissive bivalent nature of the RUNX2 promoter in
MC4 pre-OBs co-cultured directly with MM cells changed to a “mono-
valent” repressive H3K27me3 architecture (Fig. 3) [78]. Kinetic Chro-
matin Immunoprecipitation (ChIP) analyses demonstrated that GFI1
recruitment and the RUNX2 epigenetic repression in pre-OBs occurred
36-48-hours after exposure to MM cells. Importantly, this suppression
of RUNX2 by changes that were mediated by increased H3K27me3
marks on the chromatin was maintained for 4 days after MM cell re-
moval from pre-OB co-cultures and was also present in isolated BMSCs
from MM patients expanded for up to 3 weeks in the absence of MM
cells [78]. Additional study by Wang and colleagues [84], suggests the
possibility that upregulation of GFI1 and its co-repressors HDAC1, LSD1
and EZH2 in MM-exposed BMSCs may have more widespread epige-
netic effects beyond regulation of the RUNX2 gene. The chromatin-
based mechanisms responsible for the prolonged suppression of osteo-
genic differentiation may also contribute to the pathologic switch of
BMSC differentiation toward adipocytes in the context of a pro-in-
flammatory MM bone marrow environment. Recent studies reported
that in addition to being a potent transcriptional suppressor of osteo-
genic differentiation [78,79], GFI1 plays a role downstream of AMPKα
in regulating adipogenesis [84]. Overexpression of wild-type GFI1 in-
creased adipogenesis and intracellular fat droplet content of AMPKα
activated 3T3-L1 cells [84]. This argues that GFI1 with co-factors may
both suppress and shift osteogenesis of MM-BMSCs to increase adipo-
genesis, which can further contribute to maintaining the prolonged
suppression and altered phenotype of MM-BMSCs. Therapeutic sig-
nificance of GFI1 targeting in MM bone disease has been demonstrated
in a study by Adamik et al. [87], in which blockade of the p62-ZZ-
domain signaling axis resulted in inhibition of GFI1 activity and rescued
osteogenesis of myeloma-exposed preOBs. Treatment of MM-preOBs
and patient-derived BMSCs with a novel small molecule inhibitor of the
p62-ZZ domain, XRK3F2, prevented GFI1 upregulation and its sub-
sequent binding and recruitment of HDAC1 to suppress Runx2. While
XRK3F2 is not a bona fide epigenetic inhibitor, it prevented deacety-
lation of the Runx2 promoter chromatin and alleviated MM-suppressed
osteogenesis in vitro [87] as well as in the syngeneic in vivo KaLwRij
murine MM model [88] (Fig. 3).
Over the past years epigenetic mechanisms have been quite ex-
tensively studied in MM cells [89], but we are only beginning to un-
derstand epigenetic changes of the altered bone marrow compartments
such as BMSCs in the context MM exposure. The transcriptomic ana-
lyses of the MM-BMSCs has already yielded a wealth of information, but
the reported gene expression signatures are often quite variable and
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there is a lack of unified integration of the data from descriptive ana-
lyses into potential clinical applications. Furthermore, there is a great
need for genome-wide mapping of chromatin landscapes that can be
linked with the transcription profiling from MM-BMSCs in the context
of both MM-preOB cell lines and MM patient BMSCs from different
stages of disease progression. Correlating the changes in epigenetic and
transcriptional signatures in BMSCs with changes in MM cells during
MGUS to MM progression may be very informative in dissecting the
nature of tumor initiation and fostering properties of MM-BMSCs.
Furthermore, the field should consider the fact that just as is the case in
the heterogeneity and evolution of MM tumors cells, clonal divergence
and expansion may be also at play in favoring tumor-initiating and drug
resistant sub-populations of BMSCs during MM disease progression.
Since MM is a malignancy of both MM cells and the tumor-promoting
bone microenvironment, a strong understanding of the epigenomic
bases for trans-differentiation of MM-BMSCs into an altered adipogenic,
senescent-like and tumor-promoting phenotype is instrumental for fu-
ture studies. Therefore, epigenetic targeting should be evaluated more
consciously in the context of the bone environment, to ensure that the
use of epigenetic inhibitors does not adversely affect the differentiation
properties and health of bone marrow cell compartments.
2. Concluding remarks
The underlying pathogenic abnormalities responsible for MM are
multifactorial, and the abnormal bone metabolism seen in MMBD re-
sults from complex networks and numerous interactions among dif-
ferent bone cell types and their tumorigenic environment. While bone
loss diseases such as MMBD may be initiated by age-related shifts in
anabolic and catabolic responses that control bone homeostasis, it is
becoming increasingly clear that mutual co-evolution of genetically
altered plasma cells with the surrounding (aged) bone marrow cell
compartments are driving factors that orchestrate the initiation and
progression as well as the heterogenic abnormalities of MM cells [2].
The uncoupled bone remodeling is largely due to persistent impairment
of BMSCs to differentiate into functional OBs even in the absence of
active disease [9]. Studies over the past decade demonstrated that MM
exposed BMSCs are phenotypically distinct from their healthy coun-
terparts. Collectively, the evidence suggests that the prolonged sup-
pression of BMSCs differentiation to OBs results from a combination of
age-related changes and an increased inflammatory environment. These
chronic changes driven by malignant plasma cells may lead to increased
genomic instability, disturb epigenetic maintenance of gene expression
and induce the senescent-like phenotype of BMSCs in MM.
Transcriptomic analyses demonstrate that MM cell homing to bone
induces vast transcriptional changes in the interacting BMSCs, which
are associated with enhanced MM-growth and drug resistance and in-
duction of an anti-osteogenic and pro-lipogenic phenotype in BMSCs.
Cross-talk between MM cells and surrounding BMSCs results from re-
ceptor-guided direct adhesive interactions as well as soluble factors and
exosome-mediated exchange of genetic and protein regulatory cargo.
Chromatin organization in BMSCs is based upon specific patterns of
histone modifications and bivalent domains, which poises the entire
genome to enter into several developmental outcomes [90]. MM cell
exposure hijacks this epigenetic plasticity inducing corresponding
changes in chromatin modifying enzymes such as EZH2, HDAC1 and
LSD1 that shift the osteogenic differentiation potential of BMSCs to-
ward adipogenesis. MM cells appear to act primarily on multi-potential
BMSCs, as more mature OBs are largely refractory to the effects of MM
cells and can exhibit anti-MM characteristics [62]. Several classes of
epigenetic inhibitors have been developed, with several in pre-clinical
trial and/or approved for clinical use. These epigenetic inhibitors can
target the oncogenesis of MM cells [89] and their therapeutic potential
for enhancing OB differentiation as a means to repair osteolytic bone
lesions in MM has a promising future but needs further evaluations.
Treatment modalities for multiple MM (MM) patients suffering from
refractory or high-risk disease still have limited efficacy, and there are
no effective, safe bone anabolic treatment approved for MM patients.
Increased understanding of the underlying epigenetic and transcrip-
tional programs responsible for multi-potential differentiation and tu-
morigenic support of MM-BMSCs is of high clinical significance if we
are to develop new therapeutic strategies for MMBD.
Fig. 3. Epigenetic suppression of RUNX2 promoter in MM-BMSCs. RUNX2 pro-
moter in undifferentiated BMSCs exhibits bivalent promoter architecture having
both H3K4me3 and H3K27me3 chromatin marks. During OB differentiation
RUNX2 is in a transcriptionally permissive state with an open/euchromatic
promoter architecture with enhanced active chromatin marks H3K3me3 and
H3K9ac and reduced levels of repressive modification H3K27me3. MM exposure
induces binding of transcriptional repressor Gfi1 with chromatin modifiers EZH2,
HDAC1 and LSD1 to the RUNX2 promoter [78]. These modifiers deposit re-
pressive chromatin marks on RUNX2 promoter core histones and epigenetically
block its transcription. The active chromatin signature of RUNX2 changes into
repressive H3K27me3-prevalent state. Treatment of preOBs with p62-ZZ-domian
inhibitor XRK3F2 prevents upregulation and binding of GFI1 to the RUNX2 gene.
This decreases recruitment of HDAC1 and subsequent MM-induced deacetylation
of RUNX2, which leads to enhanced osteogenic differentiation [87].
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